Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older who have voluntarily signed a consent form agreeing to take part
- People diagnosed with breast cancer that has come back or spread to other parts of the body (advanced stage)
- People who have already received standard first-line (initial) treatment for their breast cancer
- People whose doctors estimate they have a life expectancy of at least 3 months
- People whose general health and ability to carry out daily activities meets a certain minimum level, based on standard medical scoring tools (confirm with trial site)
- People whose liver, kidney, and bone marrow are functioning at a basically normal level
- Women who could become pregnant must use appropriate contraception before joining the trial and for 3 months after treatment ends
Who may not be able to join:
- People who have received any other cancer treatment within the 4 weeks before joining the trial
- People with a known allergy to paclitaxel, albumin, naproxen, ibuprofen, trimethoprim, or ampicillin
- People whose blood pregnancy test comes back positive
- People who need blood-thinning (anticoagulant) medication
- People with an active infection, or who have a history of bone marrow or organ transplantation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jia Shaochang, MD, Jinling Hospital, China
Phone: +86-02580864524
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To verity the safety of Albumin-bound Paclitaxel/Granulocyte in the treatment of Recurrent/Metastatic Breast Cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.